drugset / Trial / NCT05221359

Pilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes

NCT05221359

Recruiting 8 enrolled Defymed
NaSingle-groupOpen-labelTreatment

Summary

First in Human, pilot investigation An Open Label, Monocentric, Pilot Study Evaluating Safety of ExOlin® in Patients with Poorly Controlled Type 1 Diabetes with High Glucose Fluctuations, Prone to Severe Hypoglycemia

Timeline

Start
2022-05-05
Primary completion
2026-12
Completion
2027-04

Drugs

EvaluationDrugModalityDoseRoute
Background insulin aspart Protein / enzyme biologic